A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

NCT04591626 · Completed

Last updated 2026-05-28

This clinical trial tested the medication dulaglutide in Chinese adults with type 2 diabetes to see how it affects their blood sugar levels over time.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 291 people

Who can join Ages 18+ · all sexes

Timeline Started 2020-12 · est. completion 2022-04

Where 27 sites · China

What this study is testing ClinicalTrials.gov NCT04591626 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC
Placebo Drug

Administered SC
Insulin Glargine Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04591626 ↗